Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients

Cancer Investigation

Volumn 22, Issue 3, 2004, Pages 360-367

  Nemunaitis, John ^a,b,c,e   Cunningham, C Casey ^a,b,c   Vukelja, Suetislava ^a   Ruxer, R L ^a   Adams, Ned ^a,b   Rich, Dawn ^a   Paulson, A Scott ^a   MacEachern, Jane B ^d  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Mary Crowley Medical Research Center   (United States)

^d Smith Klein Beecham   (United States)

^e Collins Bldg ^*  (United States)

Author keywords

Gemcitabine; Refractory cancer patients; Topotecan

Indexed keywords

GEMCITABINE; TOPOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TOPOTECAN; TREATMENT OUTCOME;

EID: 4744365300     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200029060     Document Type: Article

References (18)

1. Slichenmyer, W.J.; Rowinsky, E.K.; Donehower, R.C.; Kaufman, S.H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 1993, 85 (4), 271-291.
2. Barton-Burke, M. Gemcitabine: a pharmacological and clinical overview. Cancer Nurs. Apr. 1999, 22 (2), 176-183.
3. Murren, J.; Kraut, E.; Balcerzak, S.; Gams, R.; Galloway, S.; Schultz, M.; Masters, G.; Chang, A. Phase II trial of topotecan and cyclophoamide (CY) with G-CSF in high-risk small cell lung cancer (SCLC). ASCO Proc. 1998, 17 (1907), 495a.
4. Raefsky, E.L.; Hainsworth, J.D.; Burris, H.A.; Hopkins, L.G.; Greco, P.A. Phase I trial of topotecan, paclitaxel, and carboplatin in patients with advanced refractory malignancies. ASCO Proc. 1998, 17 (1920), 498a.
5. Long, G.S.; Sinibaldi, V.J.; O'Reilly, S.; Carducci, M.A.; Grochow, L.B.; Reyno, L.; Enger, C.; Eisenberger, M.A. A Phase I and pharmacologic study of suramin (S) and topotecan (T) in patients (PTS) with hormone refractory prostate cancer (HRPC). ASCO Proc. 1998, 17 (948), 247a.
6. Sandier, A.; Nemunaitis, J.; Denham, C.; von Pawel, J.; Cormier, Y.; Gatzemeier, U.; Mattson, K.; Manegold, C.; Palmer, M.C.; Gregor, A.; Nguyen, B.; Niyikiza, C.; Einhorn, L.H. Phase (G) study of cisplatin with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. Jan. 2000, 18 (1), 122-130.
7. Nagourney, R.A.; Link, J.; Kunkel, L.; Evans, S. Phase II trial of cisplatin (CDDP) and gemcitabine (DFDC) in heavily pretreated breast cancer. ASCO Proc. 1998, 17 (619), 161a.
8. Madajewicz, S.; Viola, M.; Hentschel, P.; Burns, P.; Caruso, R.; Fiore, J.; Fried, M.; Malhotra, H.; Ostrow, S.; Sugarman, S.; Viola, M. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J. Clin. Oncol. 2000, 18 (20), 3553-3557.
9. Hitt, R.; Castellano, D.; Hidalgo, M.; Garcia-Carbonero, R.; Pena, M.; Brandariz, A.; Millan, J.M.; Alvarez Vincent, J.J.; Cortes Funes, H. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann. Oncol. 1998, 9 (12), 1347-1349.
10. Greggi, S.; Salerno, M.; D'Agostino, G.; Fernandina, G.; Lorusso, D.; Manzione, L.; Mancuso, S.; Scambia, G. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 2001, 60, 19-23.
11. Sun, W.; Stevenson, J.P.; Gallagher, M.; Giantonio, B.; Algazy, K.; Haller, D.; Vaughn, D.; Raskay, B.J.; O'Dwyer, P.J. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 2001, 92 (2), 414-419.
12. Rinaldi, D.; Lormand, N.; Brierre, J.; Cole, J.; Barnes, B.; Fontenot, F.; Buller, E.; Rainey, J. A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer Investig. 2001, 19 (5), 467-474.
13. Gridelli, C. Topotecan, a recent discovery and prospects for treating tumors of the lung. Tumor 1999, 85 (6 Suppl. 1), S16-S22.
14. Steward, W.P.; Dunlop, D.J. New drugs in the treatment of non-small cell lung cancer. Ann. Oncol. 1995, 6 (Suppl. 1), 49-54.
15. Ferrigno, D.; Buccheri, G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer 2000, 29, 91-104.
16. Gridelli, C.; Cigolari, S.; Gallo, C.; Manzione, L.; Ianniello, G.P.; Frontini, L.; Ferrau, F.; Robbiati, S.F.; Adamo, V.; Gasparini, G.; Novelle, S.; Perone, F. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001, 31 (2-3), 277-284.
17. Gridelli, C.; Perrone, F.; Gallo, C.; Rossi, A.; Barletta, E.; Barzelloni, M.L.; Creazolla, S.; Gatani, T.; Fiore, F.; Guida, C.; Scognamiglio, F. Single-agent gemcitabine as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Anticancer Res. 1999, 19 (5C), 4535-4538.
18. Bianco, V.; Di Girolamo, B.; Pignatelli, E.; Speranza, I.; Florio, G.; Gemma, D.; Girolami, M.; Vietri, F.; Marchei, P. Gemcitabine as single agent therapy in advanced non-small cell lung cancer and quality of life in the elderly. Panminerva Med. 2001, 43 (1), 15-19.